Last Posted: Feb 27, 2020
- Biochemical and imaging parameters in acid sphingomyelinase deficiency: Potential utility as biomarkers.
Eskes Eline C B et al. Molecular genetics and metabolism 2020 Feb - Making Informed CHOICES: The Launch of a "Big Data" Pragmatic Trial to Improve Cholesterol Management and Prevent Heart Disease in Ontario.
Ferreira-Legere Laura E et al. Healthcare quarterly (Toronto, Ont.) 2020 Jan 22(4) 6-9 - Aspirin for Prevention of Cardiovascular Disease
AT Peters et al, JAMA Patient Page, February 18, 2020 - Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky James et al. JAMA 2020 Feb 323(7) 646-655 - Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease
M Trinder et al, JAMA Cardiology, February 11, 2020 - Autosomal recessive hypercholesterolemia: update for 2020.
D'Erasmo Laura et al. Current opinion in lipidology 2020 Jan - Familial hypercholesterolemia: Detect, treat, and ask about family.
Shah Nishant P et al. Cleveland Clinic journal of medicine 2020 Feb 87(2) 109-120 - Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia.
Rodríguez-Borjabad Cèlia et al. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2020 Jan - Step aside CRISPR, RNA editing is taking off: Making changes to the molecular messengers that create proteins might offer flexible therapies for cancer, pain or high cholesterol, in addition to genetic disorders.
S Reardon, Nature, February 4, 2020 - Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application.
Pang Jing et al. Heart, lung & circulation 2019 Dec
.png)
No hay comentarios:
Publicar un comentario